Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 501–600 of 1,000
Cheraghlou, S., Ugwu, N., & Girardi, M. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.4812 · Cited by 28
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
Wang, M., Zadeh, S. H., Pizzolla, A., Thia, K. Y. T., Gyorki, D. E., McArthur, G. A., Scolyer, R. A., Long, G. V., Wilmott, J. S., Andrews, M. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004095 · Cited by 28
Self-citationGorris, M. A. J., van der Woude, L. L., Kroeze, L. I., Bol, K. F., Verrijp, K. N., Amir, A. L., Meek, J., Textor, J. C., Figdor, C. G., & de Vries, I. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004329 · Cited by 35
Neoadjuvant treatment for stage III and IV cutaneous melanoma
Gorry, C., McCullagh, L., O’Donnell, H., Barrett, S., Schmitz, S., Barry, M. G., Curtin, K., Beausang, E. S., Barry, R., & Coyne, I. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012974.pub2 · Cited by 44
Feng, T., Li, S., Zhao, G., Li, Q., Yuan, H., Zhang, J., Gu, R. C., Ou, D., Guo, Y., Kou, Q., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00807-8 · Cited by 30
“Adjuvant or neoadjuvant therapy offers clinical benefit for several cancers, including breast cancer, colon cancer and melanoma [52–54].”
BackgroundSchoenfeld, J. D., Gjini, E., Rodig, S. J., Tishler, R. B., Rawal, B., Catalano, P. J., Uppaluri, R., Haddad, R. I., Hanna, G. J., Chau, N. G., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.05.002 · Cited by 28
Neoadjuvant therapy of locally/regionally advanced melanoma
Khunger, A., Buchwald, Z. S., Lowe, M., Khan, M. K., Delman, K. A., & Tarhini, A. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866959 · Cited by 29
Use of immunotherapy and surgery for stage IV melanoma
Molina, G., Kasumova, G. G., Qadan, M., & Boland, G. M. (2020) · Cancer · doi:10.1002/cncr.32817 · Cited by 29
“The administration of adjuvant ipilimumab or adjuvant pembrolizumab after the complete resection of stage III melanoma disease led to longer recurrence-free survival in 2 separate randomized phase 3 trials.(3,4) The FDA approved adjuvant ipilimumab in 2015 and adjuvant nivolumab in 2017 for stage III or oligometastati…”
BackgroundGuo, L., Yi, J., Zhang, A., Zheng, X., Wang, M., Fan, Y., Kong, X., & Meng, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157312 · Cited by 32
Morita, M., Okuyama, M., Akutsu, T., Ohdaira, H., Suzuki, Y., & Urashima, M. (2021) · Nutrients · doi:10.3390/nu13061987 · Cited by 27
Dimitriou, F., Hauschild, A., Mehnert, J. M., & Long, G. V. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351123 · Cited by 30
Self-citationSemyachkina-Glushkovskaya, O. V., Terskov, A. V., Khorovodov, A. P., Telnova, V., Blokhina, I., Saranceva, E. I., & Kurths, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122612 · Cited by 28
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma
Warner, A. B., & Postow, M. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1311 · Cited by 27
“The efficacy of adjuvant anti-PD-1 therapy against micrometastatic disease indicates that antigen needs not to be present in visible amounts to elicit the desired antitumor response (3).”
BackgroundTrager, M. H., Coley, S. M., Dube, G. K., Khan, S. A., Ingham, M. A., Samie, F. H., Geskin, L. J., McDonnell, D. E., Brouder, D., Saenger, Y. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000908 · Cited by 29
Fujisawa, Y., Yoshikawa, S., Minagawa, A., Takenouchi, T., Yokota, K., Uchi, H., Noma, N., Nakamura, Y., Asai, J., Kato, J., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.04.003 · Cited by 26
Targeted next generation sequencing ( NGS ) to classify melanocytic neoplasms
Zarabi, S. K., Azzato, E. M., Tu, Z. J., Ni, Y., Billings, S. D., Arbesman, J., Funchain, P., Gastman, B., Farkas, D. H., & Ko, J. S. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13695 · Cited by 26
Ahmed, F. S., Dercle, L., Goldmacher, G., Yang, H., Connors, D. E., Tang, Y., Karovic, S., Zhao, B., Carvajal, R. D., Robert, C., et al. (2020) · European Radiology · doi:10.1007/s00330-020-07249-y · Cited by 27
“First authorized in patients with advanced (metastatic or unresectable) melanoma which progressed after treatment with ipilimumab [2], pembrolizumab rapidly became a standard of care in firstline therapy for these patients and more recently as adjuvant immunotherapy in melanoma patients with lymph node involvement fol…”
BackgroundSelf-citationDe-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
Bryant, A. K., Sankar, K. N., Zhao, L., Strohbehn, G. W., Elliott, D., Moghanaki, D. M., Kelley, M. J., Ramnath, N., & Green, M. D. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.033 · Cited by 30
The end of wide local excision (WLE) margins for melanoma ?
Zijlker, L. P., Eggermont, A. M. M., & van Akkooi, A. C. J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.028 · Cited by 27
Self-citationFujimura, T., Muto, Y., & Asano, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415720 · Cited by 28
Jacques, S. K., McKeown, J., Grover, P., Johnson, D. B., Zaremba, A., Dimitriou, F., Weiser, R., Farid, M., Namikawa, K., Sullivan, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113563 · Cited by 26
Self-citationRisk-based stratification in head and neck mucosal melanoma
Moya‐Plana, A., Mangin, D., Dercle, L., Taouachi, R., Casiraghi, O., Ammari, S., Nguyen, F., Temam, S., Robert, C., & Gorphe, P. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.07.026 · Cited by 26
Self-citationTsur, N., Kogan, Y., Rehm, M., & Agur, Z. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110033 · Cited by 27
Evolution of Molecular Targets in Melanoma Treatment
Tran, K. B., Buchanan, C. M., & Shepherd, P. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200130091318 · Cited by 35
Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Pelster, M. S., & Amaria, R. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0700-z · Cited by 29
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
Шубникова, Е. В., Букатина, Т. М., Velts, N. Y., Kaperko, D. A., & Кутехова, Г. В. (2020) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2020-8-1-9-22 · Cited by 31
Optimal systemic therapy for high-risk resectable melanoma
Eggermont, A. M. M., Hamid, O., Long, G. V., & Luke, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00630-4 · Cited by 28
Self-citationRutkowski, P. L., Wysocki, P. J., Nasierowska-Guttmejer, A. M., Jeziorski, A., Wysocki, W. M., Kalinka‐Warzocha, E., Świtaj, T., Kozak, K., Kamińska‐Winciorek, G., Czarnecka, A. M., et al. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0021 · Cited by 28
Self-citationMarchisio, S., Ricci, A. A., Roccuzzo, G., Bongiovanni, E., Ortolan, E., Bertero, L., Berrino, E., Pala, V., Ponti, R., Fava, P., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05783-7 · Cited by 29
MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance
Marengo, B., Garbarino, O., Speciale, A., Monteleone, L., Traverso, N., & Domenicotti, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7346492 · Cited by 25
“In addition, in Phase 3 studies, it should be noted that this compound per se is efficacious in treating recurrent or metastatic head- and-neck squamous cell carcinoma (NCT02252042) [101], advanced urothelial carcinoma (NCT02256436) [102], nonsmall-cell lung cancer (NCT01905657) [103], and melanoma (NCT02362594) [104].”
BackgroundAdjuvant immunotherapy: the sting in the tail
Higham, C., Chatzimavridou-Grigoriadou, V., Fitzgerald, C. T., Trainer, P. J., Eggermont, A. M. M., & Lorigan, P. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.016 · Cited by 25
Self-citationItalian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
Tagliamento, M., Spagnolo, F., Poggio, F. B., Soldato, D., Conte, B., Ruelle, T., Barisione, E., Maria, A. D., Mastro, L. D., Maïo, M. D., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13315 · Cited by 25
Kartolo, A., Holstead, R. G., Khalid, S., Emack, J., Hopman, W. M., & Baetz, T. D. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000337 · Cited by 26
“138 PD-L1 inhibitor (n= 65) 20 (80) 17 (85) 28 (70) Dual immunotherapy (n= 8) 1 (4) 2 (10) 5 (12) Chemotherapy-immunotherapy (n= 6) 0 (0) 1 (5) 5 (13)”
InfluentialWang, Y., Kong, D., Wang, C., Chen, J., Li, J., Liu, Z., Li, X., Wang, Z., Yao, G., & Wang, X. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820967454 · Cited by 28
High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
Muranushi, R., Araki, K., Yokobori, T., Batbayar, C., Hoshino, K., Gantumur, D., Hagiwara, K., Yamanaka, T., Ishii, N., Tsukagoshi, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15004 · Cited by 27
Lauwyck, J., Beckwée, A., Santens, A., Schwarze, J. K., Awada, G., Vandersleyen, V., Aspeslagh, S., & Neyns, B. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000748 · Cited by 27
Shi, X., Liu, Y., Cheng, S., Hu, H., Zhang, J., Wei, M., Zhao, L., & Xin, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651622 · Cited by 28
Zaremba, A., Kramer, R., DeTemple, V. K., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M., Mechtersheimer, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.765608 · Cited by 27
“0) and (2) categorized as certainly or probably related to ICI therapy.”
BackgroundSelf-citationFelip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 26
Self-citationSystemic adjuvant therapy for high-risk cutaneous melanoma
Kobeissi, I., & Tarhini, A. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221134087 · Cited by 26
Multidisciplinary approach and treatment of acral and mucosal melanoma
Fortuna, A., & Amaral, T. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1340408 · Cited by 27
Mangla, A., Lee, C., Mirsky, M. M., Wang, M., Rothermel, L. D., Hoehn, R. S., Bordeaux, J. S., Carroll, B. T., Theuner, J., Li, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.7333 · Cited by 26
Management of in‐transit melanoma metastases: a review
Tie, E. N., Henderson, M. A., & Gyorki, D. E. (2018) · ANZ Journal of Surgery · doi:10.1111/ans.14921 · Cited by 25
“Unfortunately, ITM patients were excluded from this study.(37) The CheckMate-238 trial, compared adjuvant nivolumab to ipilimumab in 906 patients with resected stage IIIB/C and IV melanoma.”
MethodIsaksson, K., Katsarelias, D., Mikiver, R., Carneiro, A., Ny, L., & Bagge, R. O. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07448-y · Cited by 26
Approaches to High-Risk Resected Stage II and III Melanoma
Yushak, M. L., Mehnert, J. M., Luke, J. J., & Poklepovic, A. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239283 · Cited by 26
Adam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 27
Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma
Aung, T. N., Warrell, J., Martínez-Morilla, S., Gavrielatou, N., Vathiotis, I. A., Yaghoobi, V., Kluger, H. M., Gerstein, M., & Rimm, D. L. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3932 · Cited by 29
Liu, J., Xu, X., Zhong, H., Yu, M., Abuduaini, N., Zhang, S., Yang, X. Y., & Feng, B. (2024) · Biomedicines · doi:10.3390/biomedicines12071446 · Cited by 24
“In addition to PD-L1-positive patients, some PD-L1-negative patients also respond favorably to immunotherapy, suggesting that the pathological evaluation of PD-L1 level is not an accurate predictor of the effectiveness of anti-PD-L1 therapy [22–24].”
BackgroundRached, L., Peyre-Pradat, F., Spotti, M., Baldini, C., Laparra, A., Lambotte, O., Sakkal, M., Perret, A., Viansone, A. A., Michiels, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100061 · Cited by 34
Long, G. V., Nair, N., Marbach, D., Scolyer, R. A., Wilson, S., Cotting, D., Städler, N., Amaria, R. N., Ascierto, P. A., Tarhini, A. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03967-2 · Cited by 32
Self-citationBarroso‐Sousa, R., & Ott, P. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0738-2 · Cited by 25
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 31
“Indeed, the results of 2 different studies in the adjuvant setting, one comparing nivolumab to ipilimumab and pembrolizumab to placebo, respectively, showed that recurrence-free survival was longer in patients with PD-L1 positive tumors, irrespectively from the treatment [4,84].”
ResultBagge, R. O., Ny, L., Ascierto, P. A., Hodi, F. S., Larkin, J., Robert, C., Schachter, J., Weber, J. S., Long, G. V., & van Akkooi, A. C. J. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000719 · Cited by 25
Self-citationLooking into a Better Future: Novel Therapies for Metastatic Melanoma
Villani, A., Scalvenzi, M., Fabbrocini, G., Ocampo-Candiani, J., & Ocampo‐Garza, S. S. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00525-9 · Cited by 25
“A phase 3 double-blind trial evaluated pembrolizumab as adjuvant treatment in patients with high-risk stage III melanoma [13].”
BackgroundSu, Y., Li, C.-C., Lin, Y., & Hsu, C. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730949 · Cited by 24
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
Gouda, M. A., Polívka, J., Huang, H. J., Treskova, I., Pivovarčíková, K., Fikrle, T., Woznica, V., Dustin, D. J., Call, S. G., Meric‐Bernstam, F., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100357 · Cited by 24
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Plunkett, K. R., Armitage, J. D., Inderjeeth, A., McDonnell, A. M., Waithman, J. C., & Lau, P. K. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1048758 · Cited by 25
“KEYNOTE-054 2018 (5, 126) Phase III (n=1019) Resected stage III Pembrolizumab 200 mg every 3 weeks (n=513) vs placebo for 18 cycles (1 year) (n=505) 5-year RFS Pembrolizumab 55.”
BackgroundInfluentialStadler, J.-C., Keller, L., Meß, C., Bauer, A. T., Kött, J., Geidel, G., Heidrich, I., Vidal‐y‐Sy, S., Andreas, A., Stramaglia, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006456 · Cited by 24
Zhou, L., Yang, J., Zhang, K., Wang, T., Jiang, S., & Zhang, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01361 · Cited by 24
Qin, Y., Chen, S., Gui, Q., Zhang, T., Li, Y., Du, Z., Lv, Y., Du, X., Hu, Y., & Liu, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1372861 · Cited by 26
Kalsi, S., Galenkamp, A. L., Singh, R., Khosla, A. A., McGranaghan, P., & Cintolo-Gonzalez, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01611-9 · Cited by 27
The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
Keung, E. Z.-Y., & Wargo, J. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.008 · Cited by 24
Isnaldi, E., Garuti, A., Cirmena, G., Scabini, S., Rimini, E., Ferrando, L., Lia, M., Murialdo, R., Tixi, L., Carminati, E., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1879-2 · Cited by 26
“This phenomenon has been particularly evident in lung cancer and melanoma, with the introduction of novel immune-acting drugs [42, 43].”
BackgroundThe Evolution of Adjuvant Therapy for Melanoma
Cohen, J. V., & Buchbinder, E. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0858-3 · Cited by 28
Weilandt, J., Diehl, K., Schaarschmidt, M., Kiecker, F., Sasama, B., Pronk, M., Ohletz, J., Könnecke, A., Müller, V. A., Utikal, J. S., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3422 · Cited by 26
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Golay, J., & Andrea, A. E. (2020) · Antibodies · doi:10.3390/antib9020017 · Cited by 25
Cutaneous melanoma: cost of illness under Brazilian health system perspectives
da Veiga, C. R. P., da Veiga, C. P., Souza, A., Wainstein, A. J. A., de Melo, A. C., & Drummond‐Lage, A. P. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06246-1 · Cited by 24
“Anti-PD-1 treatments were not considered in the disease model’s adjuvant treatment options because to date there is no available information on overall survival [26, 27].”
BackgroundDahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
“In two randomized studies including resected malignant melanoma stage III or IV comparing pembrolizumab versus placebo and nivolumab versus ipilimumab, early results show best durable effect of the of pembrolizumab and nivolumab arms compared to the control groups with placebo and ipilimumab, respectively (difference…”
BackgroundSugiyama, K., Gordon, A., Popat, S., Okines, A. F. C., Larkin, J., & Chau, I. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104122 · Cited by 30
Self-citationClinical development of cancer vaccines
Haanen, J. B. A. G., Schumacher, T. N., Kagan, J. C., Fritsch, E. F., & Wu, C. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04241-9 · Cited by 30
Huang, Z., Zheng, S., Ding, S., Wei, Y., Chen, C., Liu, X., Li, H., & Xia, Y. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1606_20 · Cited by 23
Eckardt, J., Schroeder, C., Martus, P., Armeanu–Ebinger, S., Kelemen, O., Gschwind, A., Bonzheim, I., Eigentler, T., Amaral, T. M. S., Ossowski, S., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03939-w · Cited by 22
Khattak, M. A., Luke, J. J., Long, G. V., Ascierto, P. A., Rutkowski, P. L., Schadendorf, D., Robert, C., Grob, J., de la Cruz‐Merino, L., Vecchio, M. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.004 · Cited by 23
“Results of the phase 3 KEYNOTE-054 study showed that adjuvant pembrolizumab improved RFS and distant metastasis-free survival versus placebo in resected highrisk stage III melanoma and had manageable safety consistent with the known toxicity profile [8,9].”
BackgroundSelf-citationGiovannini, E., Bonasoni, M. P., D’Aleo, M., Tamagnini, I., Tudini, M., Fais, P., & Pelotti, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310919 · Cited by 28
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancers · doi:10.3390/cancers15164176 · Cited by 27
“The approvals for single-agent pembrolizumab and nivolumab in stage III/IV disease were based on data from KEYNOTE 054 and Checkmate 238, which demonstrated an improvement in relapse-free survival (RFS) and distant-metastasis-free survival (DMFS) with the administration of PD-1 inhibition over a placebo [72] or CTLA-4…”
MethodA twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Sato, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01474-4 · Cited by 24
Tian, J., & Quek, C. Y. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084243 · Cited by 25
The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma
Tanese, K., & Ogata, D. (2024) · Experimental Dermatology · doi:10.1111/exd.15122 · Cited by 25
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mandalà, M., Ferrari, A., Brecht, I. B., Suijkerbuijk, K. P. M., Maschke, L., Giannarelli, D., Indini, A., Ubaldi, M., Pecci, G., Atkinson, V. G., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114305 · Cited by 23
Self-citationGartrell, R. D., Marks, D. K., Rizk, E. M., Bogardus, M. H., Gerard, C. L., Barker, L. W., Fu, Y., Esancy, C. L., Li, G., Ji, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2847 · Cited by 24
Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma
Lundberg, M., Haapaniemi, A., Hagström, J., Juteau, S., Hernberg, M., Mäkitie, A. A., & Vento, S. I. (2019) · Rhinology Journal · doi:10.4193/rhin18.123 · Cited by 23
Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma
Angeles, C. V., Kang, R., Shirai, K., & Wong, S. L. (2019) · British journal of surgery · doi:10.1002/bjs.11149 · Cited by 23
Adjuvant systemic therapy in high-risk melanoma
Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000604 · Cited by 23
Current Immunotherapy Practices in Melanoma
Rothermel, L. D., Sarnaik, A. A., Khushalani, N. I., & Sondak, V. K. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.001 · Cited by 23
Satzger, I., Leiter, U., Gräger, N., Keim, U., Garbe, C., & Gutzmer, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.004 · Cited by 23
Self-citationDubois, M., Ardin, C., André, F., Scherpereel, A., & Mortier, L. (2019) · médecine/sciences · doi:10.1051/medsci/2019225 · Cited by 29
van Willigen, W. W., Bloemendal, M., Boers‐Sonderen, M. J., de Groot, J. W. B., Koornstra, R. H. T., van der Veldt, A. A. M., Haanen, J. B. A. G., Boudewijns, S., Schreibelt, G., Gerritsen, W. R., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738814 · Cited by 23
Self-citationBrabo, E. P., Moraes, A. B., & Neto, L. V. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01306-5 · Cited by 25
Podaza, E., Carri, I., Aris, M., von Euw, E., Bravo, A., Blanco, P. A., Wilczyński, J., Koile, D., Yankilevich, P., Nielsen, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01147 · Cited by 25
“Also, ICKB has been recently shown to be effective as adjuvant treatment in stage III CM patients (4, 5).”
BackgroundMolecular biology in conjunctival melanoma and the relationship to mucosal melanoma
Mikkelsen, L. H. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14536 · Cited by 25
Nahm, S., Rembielak, A., Peach, H., & Lorigan, P. C. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.06.017 · Cited by 23
“Patients who are BRAF wild type should be offered 6weekly adjuvant pembrolizumab [5].”
BackgroundSelf-citationTargeting Sialidase to PD1 Enhances T cell Function and Tumor Control
Garabedian, B. M., Bashian, E. E., Wang, X., Thompson, A. J., & Paulson, J. C. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00510 · Cited by 23
Rational combination of cancer immunotherapy in melanoma
Mandalà, M., & Rutkowski, P. L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2506-y · Cited by 23
Self-citationBensimon, A. G., Zhou, Z., Jenkins, M. D., Song, Y., Gao, W., Signorovitch, J., Krepler, C., Scherrer, E., Wang, J., & Aguiar‐Ibáñez, R. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00922-6 · Cited by 23
Newcomer, K., Robbins, K. J., Perone, J., Hinojosa, F. L., Chen, D., Jones, S., Kaufman, C. K., Weiser, R., Fields, R. C., & Tyler, D. S. (2021) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2021.101030 · Cited by 26
Kiss, I., Kühn, M., Hrušák, K., & Büchler, T. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100474 · Cited by 24
“100474.(14-74) The cancer types were breast cancer (n 1⁄4 3), colorectal cancer (n 1⁄4 1), gastroesophageal cancer (n 1⁄4 4), hepatocellular cancer (n 1⁄4 1), head and neck carcinoma”
BackgroundEfficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
Bhave, P., Hong, A., Lo, S., Johnson, R. R., Mangana, J., Johnson, D. B., Dülgar, Ö., Eroglu, Z., Yeoh, H., Haydon, A. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006629 · Cited by 22
Self-citationXu, X., Wang, M.-D., Xu, J.-H., Fan, Z., Diao, Y., Chen, Z., Jia, H., Liu, F., Zeng, Y., Wang, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322233 · Cited by 25
“These fi ndings align with the growing body of literature that underscores the potential of adjuvant immunotherapy in the management of various malignancies (32, 34 – 37).”
BackgroundKennedy, O. J., Ali, N. H., Lee, R. J., Monaghan, P. J., Adam, S., Cooksley, T., & Lorigan, P. C. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113949 · Cited by 22
“While first approved in the advanced setting, ICIs are now used widely for adjuvant and neoadjuvant treatment of earlier stage cancers [2–4].”
InfluentialSelf-citation
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.